Correction: Predictors and responses to varying durations of BTK inhibitor bridging therapy before anti-CD19 CAR-T cell therapy in patients with relapsed/refractory DLBCL - PubMed
6 hours ago
- #BTK inhibitors
- #lymphoma correction
- #CAR-T cell therapy
- The text is a correction notice for a previously published article titled 'Predictors and responses to varying durations of BTK inhibitor bridging therapy before anti-CD19 CAR-T cell therapy in patients with relapsed/refractory DLBCL'.
- It provides the article identifiers: PMID: 41878452, PMCID: PMC13006990, and DOI: 10.3389/fimmu.2026.1814535.
- The correction is for the original article with DOI: 10.3389/fimmu.2026.1674235.
- Keywords listed include BTK inhibitors, bridging therapy, chimeric antigen receptor (CAR), diffuse large B-cell lymphoma, nicotinamide phosphoribosyl transferase, and programmed cell death 1.
- The publication details for the original erratum are mentioned, including its publication date and PMID: 41727499.